Founders call review
5/30/2026
ASCO
GLUE | Monte Rosa Therapeutics — MRT-2359 + enzalutamide | mCRPC
Population is heavily pretreated — 75% had prior second-gen AR inhibitor, 80% taxane, 55% Pluvicto. The key subgroup is AR-mutant:…
ASCO
GLUE | Monte Rosa Therapeutics — MRT-2359 + enzalutamide | mCRPC
Population is heavily pretreated — 75% had prior second-gen AR inhibitor, 80% taxane, 55% Pluvicto. The key subgroup is AR-mutant:…